Glenmark Pharmaceuticals Limited is the first to launch in India a unique I.V. injection formulation, AKYNZEO® I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn. AKYNZEO® I.V. is a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute I.V. injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV.

The drug is already being marketed in the EU, the US, and Australia.